Physician profile
Sanjay Dalal
NPI 1992769699
$1,367.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $1,058 · 2021: $27.09 · 2022: $53.68 · 2023: $13.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,000.00 | 2020 | |
| Amgen INC. | $67.15 | 2019-2022 | |
| Vifor Pharma, INC. | $61.34 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $51.06 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $49.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.02 | 2020 | |
| Aurinia Pharma U.S., INC. | $15.73 | 2021 | |
| Travere Therapeutics, INC. | $13.65 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.65 | 2020 | |
| Glaxosmithkline, LLC. | $11.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$22,218.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.